Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

Published:2023-05 Issue:5 Volume:24 Page:553-562
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Choueiri Toni K,McDermott David F,Merchan Jaime,Bauer Todd M,Figlin Robert,Heath Elisabeth I,Michaelson M Dror,Arrowsmith Edward,D'Souza Anishka,Zhao Song,Roy Ananya,Perini Rodolfo,Vickery Donna,Tykodi Scott S

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

2. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

3. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2020

4. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

5. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma;McDermott;J Clin Oncol,2021

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma;Cancer Treatment Reviews;2024-09

2. Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024);European Journal of Medicinal Chemistry;2024-09

3. Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma;Annals of Oncology;2024-09

4. Renal cancer: signaling pathways and advances in targeted therapies;MedComm;2024-08

5. Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review;Medicine;2024-07-26